Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 2,665 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Phase 2 Interventional Results available

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

NCT04700449
View directory record Official record
Conditions
Moderate to Severe Ulcerative Colitis
Interventions
Double-Blind 0.2mg CBP-307, Double-Blind Placebo, Open-label CBP-307, Double-Blind 0.1mg CBP-307
Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Mission Hills, California • Hialeah, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Not applicable Interventional

Social Goals and Individual Incentives to Promote Walking in Older Adults

NCT01643538
View directory record Official record
Conditions
Physical Activity
Interventions
Financial incentive, Social Goal, Personal financial incentives & social goals, daily pedometer use and weekly feedback
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly

NCT00347555
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Aluminum Phosphate, Placebo, EBA-175 RII-NG Malaria Vaccine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA

NCT00958126
View directory record Official record
Conditions
Influenza
Interventions
CSL425, Placebo
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
1,313 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
11
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PENG Block for Arthroscopic Hip Surgery

NCT04508504
View directory record Official record
Conditions
Postoperative Pain, Hip Arthroscopy
Interventions
Preop PENG block, Placebo block, Ropivacaine 0.5% Injectable Solution, Normal Saline
Procedure · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

Trial of Oral Valproic Acid for Retinitis Pigmentosa

NCT01233609
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
Miami, Florida • Ann Arbor, Michigan • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 23, 2026, 4:18 AM EDT
Terminated Not applicable Interventional

Oral Carnitine for Cramps in Pregnancy

NCT00516516
View directory record Official record
Conditions
Muscle Cramp
Interventions
L-Carnitine, Placebo
Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 23, 2026, 4:18 AM EDT
Not yet recruiting Early Phase 1 Interventional

Guanfacine and Cromolyn Sodium for POTS: The DBPOTS Trial

NCT07757555
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome (POTS), Dysautonomia, Orthostatic Intolerance, Autonomic Nervous System Diseases
Interventions
Guanfacine (GFC), Cromolyn Sodium, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Processed Amniotic Fluid (PAF) Drops After Photorefractive Keratectomy (PRK)

NCT04281004
View directory record Official record
Conditions
Photorefractive Keratectomy
Interventions
Amniotic Fluid (AFED), Saline Solution
Biological · Other
Lead sponsor
University of Utah
Other
Eligibility
21 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nuevo Amanecer II: Translating a Stress Management Program for Latinas

NCT02931552
View directory record Official record
Conditions
Breast Neoplasms, Psychology, Social
Interventions
Nuevo Amancer-II Stress Management Program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Multiple Locations, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

NCT03425149
View directory record Official record
Conditions
Zika Virus, Zika Virus Infection
Interventions
VLA1601, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 23, 2026, 4:18 AM EDT
Active, not recruiting Phase 4 Interventional

Liraglutide Effect in Atrial Fibrillation

NCT03856632
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Liraglutide, RFM, Anti Arrhythmics, Afib Catheter Ablation
Drug · Other · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors

NCT02162719
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Ipatasertib, Paclitaxel, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
17
States / cities
Fullerton, California • Los Angeles, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

NCT01336465
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
placebo, rhuMAb Beta7
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
San Diego, California • Gainesville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Affixing Polypropylene Mesh Using Barbed Suture (Quill™ Srs) During Laparoscopic Sacrocolpopexy Randomized Controlled Trial (Quill Lsc)

NCT01551992
View directory record Official record
Conditions
Prolapse
Interventions
Quill suture vs. Interrupted suture
Procedure
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 23, 2026, 4:18 AM EDT
Terminated Phase 2 Interventional Results available

Etanercept for the Treatment of Lupus Nephritis

NCT00447265
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Etanercept, Lupus Treatment- Standard of Care, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

NCT05080764
View directory record Official record
Conditions
Acne Vulgaris
Interventions
1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fountain Valley, California • San Diego, California • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 2 Interventional

PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

NCT00690066
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes
Interventions
PROCHYMAL®, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • La Jolla, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 23, 2026, 4:18 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers

NCT05121051
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Biospecimen Collection, Broccoli Sprout/Broccoli Seed Extract Supplement, Placebo Administration, Questionnaire Administration
Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 4:18 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

NCT02101853
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Pharmacological Study, Radiation Therapy, Therapeutic Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
166
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 135 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

A Study of LAM-002A for the Prevention of Progression of COVID-19

NCT04446377
View directory record Official record
Conditions
COVID-19 Disease
Interventions
Apilimod Dimesylate Capsule, Placebo
Drug · Other
Lead sponsor
IRulya Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 23, 2026, 4:18 AM EDT
Terminated Phase 2 Interventional

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

NCT01425970
View directory record Official record
Conditions
Hepatitis C
Interventions
INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anaheim, California • La Jolla, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 23, 2026, 4:18 AM EDT
Recruiting Not applicable Interventional

Use of CereGate Therapy for Freezing of Gait in PD

NCT05292794
View directory record Official record
Conditions
Parkinson Disease, Freezing of Gait, Deep Brain Stimulation
Interventions
CereGate Software; BSN cDBS Programmer; BSN Burst Programmer
Device
Lead sponsor
CereGate Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Redwood City, California • Aurora, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 23, 2026, 4:18 AM EDT
Suspended Not applicable Interventional

Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

NCT06673095
View directory record Official record
Conditions
Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8
Interventions
Biospecimen Collection, Excision, Survey Administration
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Davis, California • Lexington, Kentucky • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 4:18 AM EDT